Nature Communications (Feb 2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- Shohei Koyama,
- Esra A. Akbay,
- Yvonne Y. Li,
- Grit S. Herter-Sprie,
- Kevin A. Buczkowski,
- William G. Richards,
- Leena Gandhi,
- Amanda J. Redig,
- Scott J. Rodig,
- Hajime Asahina,
- Robert E. Jones,
- Meghana M. Kulkarni,
- Mari Kuraguchi,
- Sangeetha Palakurthi,
- Peter E. Fecci,
- Bruce E. Johnson,
- Pasi A. Janne,
- Jeffrey A. Engelman,
- Sidharta P. Gangadharan,
- Daniel B. Costa,
- Gordon J. Freeman,
- Raphael Bueno,
- F. Stephen Hodi,
- Glenn Dranoff,
- Kwok-Kin Wong,
- Peter S. Hammerman
Affiliations
- Shohei Koyama
- Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute
- Esra A. Akbay
- Depatment of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Yvonne Y. Li
- Depatment of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Grit S. Herter-Sprie
- Depatment of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Kevin A. Buczkowski
- Department of Medical Oncology, Dana Farber Cancer Institute
- William G. Richards
- Department of Thoracic Surgery, Brigham and Women’s Hospital
- Leena Gandhi
- Department of Medical Oncology, Dana Farber Cancer Institute
- Amanda J. Redig
- Department of Medical Oncology, Dana Farber Cancer Institute
- Scott J. Rodig
- Department of Pathology, Brigham and Women’s Hospital
- Hajime Asahina
- Depatment of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Robert E. Jones
- Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute
- Meghana M. Kulkarni
- Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute
- Mari Kuraguchi
- Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute
- Sangeetha Palakurthi
- Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute
- Peter E. Fecci
- Division of Neurosurgery, Department of Surgery, Duke University Medical Center
- Bruce E. Johnson
- Depatment of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Pasi A. Janne
- Depatment of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Jeffrey A. Engelman
- Massachusetts General Hospital Cancer Center
- Sidharta P. Gangadharan
- Beth Israel Deaconess Medical Center
- Daniel B. Costa
- Beth Israel Deaconess Medical Center
- Gordon J. Freeman
- Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute
- Raphael Bueno
- Department of Thoracic Surgery, Brigham and Women’s Hospital
- F. Stephen Hodi
- Depatment of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Glenn Dranoff
- Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute
- Kwok-Kin Wong
- Depatment of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Peter S. Hammerman
- Depatment of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- DOI
- https://doi.org/10.1038/ncomms10501
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 9
Abstract
Blocking immune checkpoints is a promising strategy to treat lung cancer, but patients often become resistant to the therapy. Here, the authors analyse resistance in mouse models of lung cancer and show in mice and two patients, an increase in the expression of TIM3, which is also involved in the immune response to cancer.
